2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4373 Needle in a haystack: Optimizing an MGUS triage system

Brianna North, RN, Zhubin Gahvari, MD2, Timothy Martin Schmidt, MD3, Jeffrey Popp, RN4, Julie Punzel, RN5, Natalie S Callander, MD6, Matthew James Brunner, MD7
1 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
2 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
3 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
4 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
5 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
6 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
7 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Introduction
Triage of monoclonal gammopathy of undetermined significance (MGUS) is uniquely difficult. Although population-level MGUS screening is not currently recommended, MGUS is common and testing is obtained for a wide range of clinical scenarios, leading to a high volume of MGUS consults. Most patients will have lower risk MGUS, which does not cause clinical disease, is unlikely to cause problems in the future, and may not require specialized hematologic evaluation. Contrarily, even brief delays in the diagnosis of multiple myeloma (MM), lymphoplasmacytic lymphoma (LPL) or monoclonal gammopathies of clinical significance (MGCS) can lead to organ damage, disability or death. Unfortunately, the distinction between “likely MGUS” or “likely myeloma” may rely on unfamiliar labs (e.g., serum free light chains) or subtle patterns (e.g., hypogammaglobulinemia.) Some diagnoses, like AL amyloid or POEMS, require additional screening for non-hematologic organ involvement.

At our cancer center, hematology consults are triaged by a dedicated group of nurses (RN). In the past, RNs reached out directly to myeloma physicians on an ad hoc basis to assist with triage of MGUS consults. This led to inconsistencies in triage practices, disruption of physician and RN workflows, and occasionally delays in care.

To address these issues, we designed a series of interventions to improve MGUS triage on a rolling basis, starting in fall of 2024. Here, we review those interventions, as well as data from consecutive MGUS consults in the University of Wisconsin (UW) system.

Methods

Our quality improvement interventions fell into several categories:

(1) MD-RN communication, (2) RN education, (3) process standardization, and (4) dissemination

To improve triage team communication, we implemented a weekly, thirty-minute conference during which all new consult requests were reviewed by triage nurses and at least one myeloma physician. Disposition options included in-person visit, e-consult, or declined consult. Consult scheduling timelines were categorized as within 2 weeks, within 4 weeks, or greater than 4 weeksRNs received additional decision support with written triage guidelines and a telephone script to educate/comfort patients with lower risk MGUS. To improve clarity for referring clinicians, we developed both an MGUS-specific consult order as well as standardized e-consult template. For declined consults, a myeloma physician would call the referring provider to explain the deferral and ascertain if there were any relevant facts that might prompt reconsideration.

We collected data on consecutive patients reviewed by our triage system between 10/2/2024 and 2/27/2026. Data included date of initial consult order, reason for MGUS testing, specialty ordering the consult, our recommended disposition, and date of first visit with a hematologist. For patients where non-urgent consultation was recommended (>4 weeks between request and visit), we manually reviewed charts to see if any adverse events plausibly related to the plasma cell disorder occurred.

Results

Our data included 432 consecutive patients who had an MGUS consult order in the UW system. 57% of consults came from primary care, with rheumatology and neurology leading among specialty referrals. 64 patients were ultimately determined to have clinically significant lymphoid diseases including active or smoldering MM, LPL, or AL amyloid. For these patients, median time from consult order to visit was 13.5 days. For patients where the triage meeting recommendation was >4 weeks from consult order date,manual chart review did not reveal any instances where MGUS-related morbidity occurred prior to index hematology visit. 17% of consult requests were able to be deferred, either due to (1) no MGUS present or (2) referring clinician being amenable to monitoring MGUS themselves after a phone call from a myeloma physician.

Discussion

Our project demonstrates the utility and safety of systematic improvements to MGUS triage in a large academic setting. Sick patients were seen quickly, and patients triaged as non-urgent did not have any unexpected MGUS-related morbidity between their consult order and index visit. Almost 20% of consult requests were satisfactorily resolved with a phone call to the referring clinician. With an aging global population and the potential for broader MGUS screening guidelines, novel triage and risk stratification approaches will be needed to meet this increasing demand.

Matthew James Brunner, MD: No relevant conflicts of interest to declare.